| Code | CSB-RA980158MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to reference antibody BAT5906, targeting vascular endothelial growth factor (VEGF). VEGF is a critical signaling protein that regulates angiogenesis, the formation of new blood vessels from existing vasculature. It plays essential roles in both physiological processes such as wound healing and embryonic development, and pathological conditions including tumor growth and metastasis. VEGF overexpression is implicated in various cancers, age-related macular degeneration, diabetic retinopathy, and other neovascular disorders, making it a significant therapeutic target in oncology and ophthalmology research.
BAT5906 serves as the reference standard for this biosimilar product, providing researchers with a cost-effective alternative for investigating VEGF-mediated pathways and disease mechanisms. This antibody is suitable for studies examining angiogenesis regulation, tumor microenvironment dynamics, and VEGF signaling cascades. It supports investigations into anti-angiogenic strategies and helps elucidate the role of VEGF in vascular permeability and endothelial cell proliferation across various experimental models.
There are currently no reviews for this product.